Structure	O
-	O
Activity	O
Relationship	O
of	O
Cinnamaldehyde	O
Analogs	O
as	O
Inhibitors	O
of	O
AI	O
-	O
2	O
Based	O
Quorum	O
Sensing	O
and	O
Their	O
Effect	O
on	O
Virulence	O
of	O
Vibrio	B-OG
spp	I-OG

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
GB	O
TC	O
HJN	O
SVC	O
.	O

Performed	O
the	O
experiments	O
:	O
GB	O
UH	O
SC	O
PC	O
.	O

Analyzed	O
the	O
data	O
:	O
GB	O
TC	O
HJN	O
SVC	O
PC	O
LM	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
UH	O
SC	O
SVC	O
PC	O
LM	O
.	O

Wrote	O
the	O
paper	O
:	O
GB	O
TC	O
HJN	O
.	O

Background	O

Many	O
bacteria	B-OG
,	O
including	O
Vibrio	B-OG
spp	I-OG
.,	O
regulate	O
virulence	O
gene	O
expression	O
in	O
a	O
cell	O
-	O
density	O
dependent	O
way	O
through	O
a	O
communication	O
process	O
termed	O
quorum	O
sensing	O
(	O
QS	O
).	O

Hence	O
,	O
interfering	O
with	O
QS	O
could	O
be	O
a	O
valuable	O
novel	O
antipathogenic	O
strategy	O
.	O

Cinnamaldehyde	O
has	O
previously	O
been	O
shown	O
to	O
inhibit	O
QS	O
-	O
regulated	O
virulence	O
by	O
decreasing	O
the	O
DNA	O
-	O
binding	O
ability	O
of	O
the	O
QS	O
response	O
regulator	O
LuxR	B-GP
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
structure	O
-	O
activity	O
relationship	O
of	O
cinnamaldehyde	O
analogs	O
.	O

Methodology	O
/	O
Principal	O
Findings	O

By	O
evaluating	O
the	O
QS	O
inhibitory	O
activity	O
of	O
a	O
series	O
of	O
cinnamaldehyde	O
analogs	O
,	O
structural	O
elements	O
critical	O
for	O
autoinducer	O
-	O
2	O
QS	O
inhibition	O
were	O
identified	O
.	O

These	O
include	O
an	O
α	O
,	O
β	O
unsaturated	O
acyl	O
group	O
capable	O
of	O
reacting	O
as	O
Michael	O
acceptor	O
connected	O
to	O
a	O
hydrophobic	O
moiety	O
and	O
a	O
partially	O
negative	O
charge	O
.	O

The	O
most	O
active	O
cinnamaldehyde	O
analogs	O
were	O
found	O
to	O
affect	O
the	O
starvation	O
response	O
,	O
biofilm	O
formation	O
,	O
pigment	O
production	O
and	O
protease	B-GP
production	O
in	O
Vibrio	B-OG
spp	I-OG
in	O
vitro	O
,	O
while	O
exhibiting	O
low	O
cytotoxicity	O
.	O

In	O
addition	O
,	O
these	O
compounds	O
significantly	O
increased	O
the	O
survival	O
of	O
the	O
nematode	B-OG
Caenorhabditis	B-OG
elegans	I-OG
infected	O
with	O
Vibrio	B-OG
anguillarum	I-OG
,	O
Vibrio	B-OG
harveyi	I-OG
and	O
Vibrio	B-OG
vulnificus	I-OG
.	O

Conclusions	O
/	O
Significance	O

Several	O
new	O
and	O
more	O
active	O
cinnamaldehyde	O
analogs	O
were	O
discovered	O
and	O
they	O
were	O
shown	O
to	O
affect	O
Vibrio	B-OG
spp	I-OG
.	O
virulence	O
factor	O
production	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Although	O
ligands	O
for	O
LuxR	B-GP
have	O
not	O
been	O
identified	O
so	O
far	O
,	O
the	O
nature	O
of	O
different	O
cinnamaldehyde	O
analogs	O
and	O
their	O
effect	O
on	O
the	O
DNA	O
binding	O
ability	O
of	O
LuxR	B-GP
suggest	O
that	O
these	O
compounds	O
act	O
as	O
LuxR	B-GP
-	O
ligands	O
.	O

Introduction	O

Many	O
bacteria	B-OG
,	O
including	O
Vibrio	B-OG
spp	I-OG
.,	O
regulate	O
gene	O
expression	O
in	O
a	O
cell	O
-	O
density	O
dependent	O
way	O
through	O
a	O
communication	O
process	O
termed	O
quorum	O
sensing	O
(	O
QS	O
).	O

In	O
Vibrio	B-OG
spp	I-OG
.	O

QS	O
is	O
mediated	O
by	O
three	O
types	O
of	O
synergistically	O
acting	O
signalling	O
molecules	O
:	O
acyl	O
-	O
homoserine	O
lactones	O
(	O
AHL	O
),	O
cholera	O
-	O
autoinducer	O
-	O
1	O
(	O
CAI	O
-	O
1	O
)	O
and	O
a	O
mixture	O
of	O
interconvertible	O
molecules	O
collectively	O
called	O
autoinducer	O
-	O
2	O
(	O
AI	O
-	O
2	O
)	O
[	O
1	O
]–[	O
4	O
].	O

The	O
key	O
enzymes	O
in	O
the	O
production	O
of	O
these	O
molecules	O
are	O
LuxN	B-GP
,	O
LuxS	B-GP
and	O
CqsA	B-GP
for	O
AHL	O
,	O
AI	O
-	O
2	O
and	O
CAI	O
-	O
1	O
,	O
respectively	O
[	O
4	O
].	O

In	O
response	O
to	O
binding	O
of	O
the	O
signalling	O
molecules	O
to	O
their	O
cognate	O
receptor	O
,	O
a	O
phosphorelay	O
cascade	O
is	O
induced	O
.	O

At	O
low	O
population	O
density	O
only	O
basal	O
amounts	O
of	O
diffusible	O
signal	O
molecules	O
are	O
produced	O
,	O
and	O
in	O
this	O
situation	O
the	O
receptor	O
will	O
act	O
as	O
a	O
kinase	B-GP
,	O
resulting	O
in	O
the	O
phosphorylation	O
of	O
the	O
downstream	O
response	O
regulator	O
LuxO	B-GP
through	O
a	O
cascade	O
involving	O
LuxU	B-GP
[	O
5	O
].	O

Phosphorylation	O
activates	O
LuxO	B-GP
,	O
resulting	O
in	O
the	O
production	O
of	O
small	O
regulatory	O
RNAs	O
[	O
6	O
]–[	O
7	O
].	O

These	O
small	O
RNAs	O
,	O
together	O
with	O
the	O
chaperone	B-GP
protein	I-GP
Hfq	B-GP
,	O
destabilize	O
mRNA	O
encoding	O
the	O
response	O
regulator	O
LuxR	B-GP
.	O

However	O
,	O
when	O
population	O
density	O
is	O
sufficiently	O
high	O
,	O
signalling	O
molecules	O
will	O
bind	O
to	O
their	O
cognate	O
receptor	O
and	O
the	O
latter	O
will	O
act	O
as	O
phosphatase	B-GP
,	O
leading	O
to	O
a	O
dephosphorylation	O
of	O
LuxO	B-GP
[	O
7	O
].	O

Since	O
unphosphorylated	O
LuxO	B-GP
is	O
inactive	O
,	O
no	O
small	O
regulatory	O
RNAs	O
will	O
be	O
formed	O
and	O
the	O
LuxR	B-GP
mRNA	O
remains	O
stable	O
,	O
resulting	O
in	O
the	O
production	O
of	O
LuxR	B-GP
and	O
ultimately	O
an	O
altered	O
gene	O
expression	O
pattern	O
.	O

The	O
virulence	O
of	O
several	O
Vibrio	B-OG
spp	I-OG
.	O
was	O
previously	O
found	O
to	O
be	O
controlled	O
by	O
multiple	O
QS	O
systems	O
making	O
QS	O
inhibition	O
an	O
interesting	O
antipathogenic	O
strategy	O
[	O
8	O
]–[	O
10	O
].	O

Cinnamaldehyde	O
is	O
known	O
to	O
affect	O
AI	O
-	O
2	O
QS	O
[	O
10	O
],	O
[	O
11	O
]	O
and	O
we	O
have	O
previously	O
shown	O
that	O
cinnamaldehyde	O
disrupts	O
QS	O
-	O
regulated	O
virulence	O
in	O
Vibrio	B-OG
spp	I-OG
.	O
by	O
decreasing	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
the	O
response	O
regulator	O
LuxR	B-GP
[	O
10	O
].	O

However	O
,	O
the	O
exact	O
structural	O
elements	O
required	O
for	O
QS	O
inhibitory	O
activity	O
remain	O
unclear	O
.	O

The	O
development	O
of	O
new	O
antipathogenic	O
agents	O
based	O
on	O
cinnamaldehyde	O
requires	O
the	O
understanding	O
of	O
the	O
structural	O
reason	O
for	O
LuxR	B-GP
inhibition	O
.	O

To	O
address	O
this	O
,	O
a	O
small	O
library	O
of	O
cinnamaldehyde	O
analogs	O
was	O
screened	O
for	O
their	O
inhibitory	O
effect	O
on	O
QS	O
in	O
Vibrio	B-OG
spp	I-OG
.	O

The	O
structural	O
elements	O
required	O
for	O
QS	O
inhibition	O
were	O
identified	O
and	O
a	O
mechanism	O
of	O
action	O
is	O
proposed	O
.	O

The	O
effect	O
of	O
selected	O
cinnamaldehyde	O
analogs	O
on	O
Vibrio	B-OG
spp	I-OG
.	O
virulence	O
was	O
evaluated	O
in	O
vitro	O
and	O
in	O
vivo	O
in	O
a	O
Caenorhabditis	B-OG
elegans	I-OG
assay	O
.	O

Results	O
and	O
Discussion	O

Cinnamaldehyde	O
and	O
cinnamaldehyde	O
analogs	O
do	O
not	O
affect	O
bacterial	O
growth	O
or	O
bioluminescence	O

When	O
used	O
in	O
concentrations	O
up	O
to	O
250	O
µM	O
,	O
cinnamaldehyde	O
and	O
most	O
analogs	O
(	O
Fig	O
.	O
1	O
)	O
did	O
not	O
affect	O
the	O
growth	O
of	O
the	O
different	O
Vibrio	B-OG
strains	O
used	O
in	O
this	O
study	O
,	O
the	O
exception	O
being	O
3	O
,	O
4	O
-	O
dichloro	O
-	O
cinnamaldehyde	O
and	O
4	O
-	O
nitro	O
-	O
cinnamaldehyde	O
(	O
MIC	O
≥	O
100	O
µM	O
and	O
MIC	O
≥	O
50	O
µM	O
,	O
respectively	O
)	O
(	O
data	O
not	O
shown	O
).	O

In	O
all	O
experiments	O
,	O
compounds	O
were	O
used	O
in	O
concentrations	O
below	O
the	O
minimal	O
inhibitory	O
concentration	O
.	O

To	O
rule	O
out	O
direct	O
interference	O
with	O
bioluminescence	O
,	O
all	O
compounds	O
were	O
assessed	O
for	O
their	O
effect	O
on	O
the	O
bioluminescence	O
of	O
an	O
E	B-OG
.	I-OG
coli	I-OG
DH5α	I-OG
pBluelux	I-OG
strain	O
containing	O
the	O
luxCDABE	O
genes	O
,	O
but	O
none	O
of	O
the	O
compounds	O
directly	O
affected	O
bioluminescence	O
.	O

Cinnamaldehyde	O
and	O
cinnamaldehyde	O
analogs	O
used	O
in	O
the	O
present	O
study	O
.	O

Several	O
cinnamaldehyde	O
analogs	O
affect	O
AI	O
-	O
2	O
-	O
regulated	O
bioluminescence	O

To	O
screen	O
for	O
AI	O
-	O
2	O
inhibition	O
,	O
the	O
effect	O
of	O
all	O
compounds	O
on	O
bioluminescence	O
of	O
V	B-OG
.	I-OG
harveyi	I-OG
BB170	I-OG
was	O
assessed	O
(	O
Table	O
1	O
).	O

Five	O
cinnamaldehyde	O
analogs	O
were	O
previously	O
shown	O
to	O
affect	O
AI	O
-	O
2	O
QS	O
.	O

Two	O
of	O
these	O
non	O
-	O
halogen	O
substituted	O
cinnamaldehyde	O
analogs	O
,	O
i	O
.	O
e	O
.	O
2	O
-	O
nitro	O
-	O
cinnamaldehyde	O
(	O
2	O
)	O
and	O
4	O
-	O
nitro	O
-	O
cinnamaldehyde	O
(	O
3	O
),	O
were	O
at	O
least	O
as	O
active	O
in	O
blocking	O
AI	O
-	O
2	O
QS	O
as	O
the	O
unsubstituted	O
cinnamaldehyde	O
(	O
1	O
)	O
[	O
10	O
].	O

In	O
the	O
present	O
study	O
,	O
several	O
halogenated	O
compounds	O
were	O
found	O
to	O
be	O
more	O
active	O
than	O
the	O
unsubstituted	O
cinnamaldehyde	O
.	O

These	O
include	O
3	O
,	O
4	O
-	O
dichloro	O
-	O
cinnamaldehyde	O
(	O
9	O
),	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
-	O
pentafluoro	O
-	O
cinnamaldehyde	O
(	O
12	O
)	O
and	O
4	O
-	O
chloro	O
-	O
3	O
-	O
trifluoromethyl	O
-	O
cinnamaldehyde	O
(	O
14	O
).	O

3	O
,	O
4	O
-	O
Dichloro	O
-	O
cinnamaldehyde	O
(	O
9	O
)	O
reduced	O
the	O
QS	O
-	O
regulated	O
bioluminescence	O
by	O
99	O
±	O
1	O
%	O
without	O
interfering	O
with	O
the	O
bacterial	O
growth	O
of	O
V	B-OG
.	I-OG
harveyi	I-OG
BB170	I-OG
.	O

None	O
of	O
the	O
halogenated	O
cinnamic	O
acid	O
analogs	O
resulted	O
in	O
an	O
increased	O
QS	O
inhibition	O
compared	O
to	O
the	O
corresponding	O
cinnamaldehyde	O
analog	O
or	O
to	O
the	O
unsubstituted	O
cinnamaldehyde	O
.	O

Methyl	O
-	O
styryl	O
sulfone	O
(	O
15	O
),	O
cinnamamide	O
(	O
18	O
)	O
and	O
(	O
E	O
)-	O
4	O
-	O
phenyl	O
-	O
3	O
-	O
buten	O
-	O
2	O
-	O
one	O
(	O
22	O
)	O
(	O
50	O
µM	O
)	O
resulted	O
in	O
a	O
30	O
±	O
11	O
%,	O
28	O
±	O
9	O
%	O
and	O
35	O
±	O
16	O
%	O
inhibition	O
.	O

In	O
addition	O
,	O
(	O
E	O
)-	O
4	O
-	O
phenyl	O
-	O
2	O
-	O
butanone	O
(	O
23	O
)	O
and	O
1	O
-	O
acetyl	O
-	O
1	O
-	O
cyclohexene	O
(	O
24	O
)	O
were	O
only	O
active	O
at	O
higher	O
concentrations	O
(	O
100	O
µM	O
)	O
while	O
no	O
QS	O
inhibitory	O
activity	O
was	O
observed	O
for	O
3	O
-	O
phenylpropionaldehyde	O
(	O
16	O
),	O
3	O
-	O
phenylpropionic	O
acid	O
(	O
17	O
),	O
cinnamyl	O
alcohol	O
(	O
20	O
)	O
and	O
methyl	O
cinnamate	O
(	O
21	O
).	O

Cinnamaldehyde	O
analogs	O
in	O
which	O
the	O
aromatic	O
ring	O
was	O
replaced	O
by	O
an	O
alkyl	O
moiety	O
,	O
but	O
which	O
still	O
contain	O
the	O
acrolein	O
group	O
,	O
proved	O
also	O
to	O
be	O
active	O
AI	O
-	O
2	O
QS	O
inhibitors	O
.	O
(	O
E	O
)-	O
2	O
-	O
Pentenal	O
(	O
25	O
),	O
(	O
E	O
)-	O
2	O
-	O
tridecenal	O
(	O
27	O
),	O
methyl	O
-(	O
E	O
)-	O
2	O
-	O
nonenoate	O
(	O
28	O
)	O
and	O
(	O
E	O
)-	O
2	O
-	O
heptenal	O
(	O
35	O
)	O
were	O
at	O
least	O
as	O
active	O
in	O
inhibiting	O
AI	O
-	O
2	O
QS	O
as	O
cinnamaldehyde	O
.	O
(	O
E	O
)-	O
2	O
-	O
Nonenal	O
(	O
26	O
),	O
(	O
E	O
)-	O
3	O
-	O
decen	O
-	O
2	O
-	O
one	O
(	O
30	O
),	O
(	O
E	O
)-	O
3	O
-	O
nonen	O
-	O
2	O
-	O
one	O
(	O
31	O
),	O
(	O
E	O
)-	O
3	O
-	O
octen	O
-	O
2	O
-	O
one	O
(	O
36	O
),	O
(	O
E	O
)-	O
2	O
-	O
octenal	O
(	O
37	O
),	O
(	O
E	O
)-	O
2	O
-	O
decenal	O
(	O
39	O
),	O
(	O
E	O
)-	O
2	O
-	O
undecenal	O
(	O
40	O
)	O
and	O
(	O
E	O
)-	O
2	O
-	O
dodecenal	O
(	O
41	O
)	O
led	O
to	O
a	O
more	O
pronounced	O
inhibition	O
of	O
bioluminescence	O
compared	O
to	O
cinnamaldehyde	O
(	O
1	O
).	O

When	O
assayed	O
at	O
a	O
higher	O
concentration	O
(	O
100	O
µM	O
),	O
(	O
E	O
)-	O
2	O
-	O
nonenal	O
(	O
26	O
),	O
(	O
E	O
)-	O
3	O
-	O
decen	O
-	O
2	O
-	O
one	O
(	O
30	O
)	O
and	O
(	O
E	O
)-	O
3	O
-	O
nonen	O
-	O
2	O
-	O
one	O
(	O
31	O
)	O
almost	O
completely	O
inhibited	O
bioluminescence	O
.	O
(	O
E	O
)-	O
2	O
-	O
nonen	O
-	O
1	O
-	O
ol	O
(	O
33	O
),	O
(	O
E	O
)-	O
2	O
-	O
hexen	O
-	O
1	O
-	O
al	O
(	O
34	O
)	O
and	O
2	O
-	O
octenoic	O
acid	O
(	O
38	O
)	O
were	O
less	O
active	O
inhibitors	O
of	O
AI	O
-	O
2	O
regulated	O
bioluminescence	O
,	O
while	O
2	O
-	O
pentenoic	O
acid	O
(	O
29	O
)	O
and	O
5	O
-	O
methyl	O
-	O
2	O
-	O
hepten	O
-	O
4	O
-	O
one	O
(	O
32	O
)	O
had	O
no	O
effect	O
.	O

Based	O
on	O
these	O
results	O
,	O
cinnamaldehyde	O
(	O
1	O
),	O
2	O
-	O
nitro	O
-	O
cinnamaldehyde	O
(	O
2	O
),	O
3	O
,	O
4	O
-	O
dichloro	O
-	O
cinnamaldehyde	O
(	O
9	O
),	O
(	O
E	O
)-	O
4	O
-	O
phenyl	O
-	O
3	O
-	O
buten	O
-	O
2	O
-	O
one	O
(	O
22	O
),	O
(	O
E	O
)-	O
3	O
-	O
decen	O
-	O
2	O
-	O
one	O
(	O
30	O
),	O
(	O
E	O
)-	O
2	O
-	O
pentenal	O
(	O
25	O
)	O
and	O
(	O
E	O
)-	O
2	O
-	O
nonenal	O
(	O
26	O
)	O
were	O
selected	O
for	O
further	O
experiments	O
.	O

Inhibition	O
of	O
QS	O
-	O
regulated	O
bioluminescence	O
in	O
V	B-OG
.	I-OG
harveyi	I-OG
BB170	I-OG
(	O
activity	O
is	O
expressed	O
as	O
the	O
%	O
inhibition	O
of	O
the	O
bioluminescence	O
signal	O
of	O
the	O
untreated	O
control	O
±	O
standard	O
deviation	O
;	O
n	O
≥	O
48	O
).	O

Code	O
*	O

Compound	O

Reduction	O
in	O
bioluminescence	O
(%	O
inhibition	O
compared	O
to	O
the	O
untreated	O
control	O
±	O
SD	O
)	O
when	O
used	O
in	O
the	O
following	O
concentrations	O
:	O

50	O
µM	O

100	O
µM	O

1	O

Cinnamaldehyde	O
**	O

22	O
±	O
4	O

65	O
±	O
13	O

2	O

2	O
-	O
Nitro	O
-	O
cinnamaldehyde	O
**	O

25	O
±	O
5	O

62	O
±	O
7	O

3	O

4	O
-	O
Nitro	O
-	O
cinnamaldehyde	O
**	O

33	O
±	O
7	O

ND	O

4	O

2	O
-	O
Methoxy	O
-	O
cinnamaldehyde	O
**	O

NS	O

14	O
±	O
6	O

5	O

4	O
-	O
Methoxy	O
-	O
cinnamaldehyde	O
**	O

16	O
±	O
4	O

34	O
±	O
9	O

6	O

4	O
-	O
Dimethylamino	O
-	O
cinnamaldehyde	O
**	O

NS	O

17	O
±	O
1	O

7	O

4	O
-	O
Trifluoromethyl	O
-	O
cinnamaldehyde	O

19	O
±	O
8	O

21	O
±	O
7	O

8	O

4	O
-	O
Trifluoromethyl	O
cinnamic	O
acid	O

8	O
±	O
1	O

11	O
±	O
1	O

9	O

3	O
,	O
4	O
-	O
Dichloro	O
-	O
cinnamaldehyde	O

47	O
±	O
7	O

99	O
±	O
1	O

10	O

4	O
-	O
Chloro	O
-	O
cinnamaldehyde	O

27	O
±	O
2	O

78	O
±	O
5	O

11	O

4	O
-	O
Chloro	O
-	O
cinnamic	O
acid	O

14	O
±	O
16	O

20	O
±	O
14	O

12	O

2	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
-	O
Pentafluoro	O
-	O
cinnamaldehyde	O

44	O
±	O
14	O

95	O
±	O
3	O

13	O

2	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
-	O
Pentafluoro	O
-	O
cinnamic	O
acid	O

33	O
±	O
6	O

41	O
±	O
8	O

14	O

4	O
-	O
Chloro	O
-	O
3	O
-	O
trifluoromethyl	O
-	O
cinnamaldehyde	O

45	O
±	O
21	O

97	O
±	O
2	O

15	O

Methyl	O
-	O
styryl	O
sulfone	O

30	O
±	O
11	O

73	O
±	O
6	O

16	O

3	O
-	O
Phenylpropionaldehyde	O

NS	O

NS	O

17	O

3	O
-	O
Phenylpropionic	O
acid	O

NS	O

NS	O

18	O

Cinnamamide	O

28	O
±	O
9	O

61	O
±	O
20	O

19	O

Cinnamic	O
acid	O

NS	O

25	O
±	O
20	O

20	O

Cinnamyl	O
alcohol	O

NS	O

NS	O

21	O

Methyl	O
cinnamate	O

NS	O

NS	O

22	O

(	O
E	O
)-	O
4	O
-	O
Phenyl	O
-	O
3	O
-	O
buten	O
-	O
2	O
-	O
one	O

35	O
±	O
16	O

78	O
±	O
9	O

23	O

4	O
-	O
Phenyl	O
-	O
2	O
-	O
butanone	O

NS	O

13	O
±	O
4	O

24	O

1	O
-	O
Acetyl	O
-	O
1	O
-	O
cyclohexene	O

NS	O

16	O
±	O
6	O

25	O

(	O
E	O
)-	O
2	O
-	O
Pentenal	O

34	O
±	O
12	O

58	O
±	O
22	O

26	O

(	O
E	O
)-	O
2	O
-	O
Nonenal	O

63	O
±	O
3	O

98	O
±	O
2	O

27	O

(	O
E	O
)-	O
2	O
-	O
Tridecenal	O

36	O
±	O
19	O

56	O
±	O
21	O

28	O

Methyl	O
-(	O
E	O
)-	O
2	O
-	O
nonenoate	O

32	O
±	O
5	O

59	O
±	O
8	O

29	O

2	O
-	O
Pentenoic	O
acid	O

NS	O

NS	O

30	O

(	O
E	O
)-	O
3	O
-	O
Decen	O
-	O
2	O
-	O
one	O

80	O
±	O
11	O

99	O
±	O
1	O

31	O

(	O
E	O
)-	O
3	O
-	O
Nonen	O
-	O
2one	O

43	O
±	O
5	O

99	O
±	O
1	O

32	O

5	O
-	O
Methyl	O
-	O
2	O
-	O
hepten	O
-	O
4	O
-	O
one	O

NS	O

NS	O

33	O

(	O
E	O
)-	O
2	O
-	O
Nonen	O
-	O
1	O
-	O
ol	O

NS	O

17	O
±	O
9	O

34	O

(	O
E	O
)-	O
2	O
-	O
Hexen	O
-	O
1	O
-	O
al	O

18	O
±	O
8	O

35	O
±	O
3	O

35	O

(	O
E	O
)-	O
2	O
-	O
Heptenal	O

28	O
±	O
6	O

55	O
±	O
1	O

36	O

(	O
E	O
)-	O
3	O
-	O
Octen	O
-	O
2	O
-	O
one	O

48	O
±	O
1	O

80	O
±	O
3	O

37	O

(	O
E	O
)-	O
2	O
-	O
Octenal	O

41	O
±	O
6	O

71	O
±	O
4	O

38	O

2	O
-	O
Octenoic	O
acid	O

27	O
±	O
8	O

36	O
±	O
1	O

39	O

(	O
E	O
)-	O
2	O
-	O
Decenal	O

57	O
±	O
6	O

90	O
±	O
6	O

40	O

(	O
E	O
)-	O
2	O
-	O
Undecenal	O

75	O
±	O
9	O

94	O
±	O
6	O

41	O

(	O
E	O
)-	O
2	O
-	O
Dodecenal	O

71	O
±	O
3	O

87	O
±	O
11	O

;	O
Code	O
refers	O
to	O
structures	O
in	O
Figure	O
1	O
.	O

;	O
previously	O
assessed	O
for	O
their	O
effect	O
on	O
AI	O
-	O
2	O
quorum	O
sensing	O
[	O
10	O
].	O

ND	O
:	O
not	O
determined	O
due	O
to	O
growth	O
inhibition	O
when	O
used	O
at	O
this	O
concentration	O
.	O

NS	O
:	O
compound	O
did	O
not	O
result	O
in	O
a	O
significant	O
inhibition	O
of	O
the	O
bioluminescence	O
signal	O
(	O
p	O
>	O
0	O
.	O
05	O
;	O
independent	O
sample	O
t	O
-	O
test	O
).	O

Cinnamaldehyde	O
and	O
cinnamaldehyde	O
analogs	O
decrease	O
the	O
DNA	O
-	O
binding	O
ability	O
of	O
LuxR	B-GP

It	O
was	O
previously	O
shown	O
that	O
cinnamaldehyde	O
inhibits	O
AI	O
-	O
2	O
QS	O
by	O
decreasing	O
the	O
DNA	O
-	O
binding	O
ability	O
of	O
LuxR	B-GP
to	O
its	O
promoter	O
DNA	O
[	O
10	O
].	O

To	O
assess	O
whether	O
the	O
analogs	O
also	O
target	O
LuxR	B-GP
and	O
have	O
the	O
same	O
mechanism	O
of	O
action	O
,	O
the	O
effect	O
of	O
the	O
selected	O
compounds	O
on	O
bioluminescence	O
was	O
determined	O
in	O
various	O
V	B-OG
.	I-OG
harveyi	I-OG
QS	O
mutants	O
(	O
Table	O
2	O
).	O

The	O
selected	O
compounds	O
were	O
found	O
to	O
inhibit	O
bioluminescence	O
in	O
all	O
mutants	O
tested	O
,	O
indicating	O
that	O
the	O
target	O
of	O
these	O
compounds	O
is	O
the	O
downstream	O
transcriptional	B-GP
regulatory	I-GP
protein	I-GP
LuxR	B-GP
(	O
data	O
not	O
shown	O
).	O

To	O
further	O
investigate	O
their	O
effect	O
on	O
the	O
DNA	O
binding	O
ability	O
of	O
LuxR	B-GP
,	O
a	O
fluorescently	O
labelled	O
fragment	O
of	O
a	O
V	B-OG
.	I-OG
harveyi	I-OG
consensus	O
LuxR	B-GP
binding	O
sequence	O
[	O
12	O
]	O
was	O
incubated	O
together	O
with	O
purified	O
LuxR	B-GP
protein	O
in	O
the	O
presence	O
and	O
absence	O
of	O
cinnamaldehyde	O
analogs	O
.	O

Incubation	O
of	O
LuxR	B-GP
with	O
this	O
DNA	O
fragment	O
in	O
the	O
absence	O
of	O
QS	O
inhibitors	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
anisotropy	O
(	O
Fig	O
.	O
2	O
).	O

When	O
LuxR	B-GP
was	O
incubated	O
with	O
this	O
DNA	O
fragment	O
in	O
the	O
presence	O
of	O
cinnamaldehyde	O
,	O
2	O
-	O
nitro	O
-	O
cinnamaldehyde	O
,	O
(	O
E	O
)-	O
4	O
-	O
phenyl	O
-	O
3	O
-	O
buten	O
-	O
2	O
-	O
one	O
,	O
(	O
E	O
)-	O
2	O
-	O
pentenal	O
,	O
(	O
E	O
)-	O
3	O
-	O
decen	O
-	O
2	O
-	O
one	O
,	O
(	O
E	O
)-	O
2	O
-	O
nonenal	O
or	O
3	O
,	O
4	O
-	O
dichloro	O
-	O
cinnamaldehyde	O
,	O
binding	O
to	O
DNA	O
was	O
strongly	O
inhibited	O
(	O
Fig	O
.	O
2	O
),	O
indicating	O
that	O
these	O
compounds	O
inhibit	O
AI	O
-	O
2	O
mediated	O
QS	O
by	O
decreasing	O
the	O
DNA	O
-	O
binding	O
ability	O
of	O
LuxR	B-GP
.	O

LuxR	B-GP
DNA	O
binding	O
and	O
dissociation	O
constants	O
.	O

A	O
.	O

DNA	O
binding	O
of	O
LuxR	B-GP
in	O
the	O
absence	O
and	O
presence	O
of	O
cinnamaldehyde	O
or	O
a	O
cinnamaldehyde	O
analog	O
(	O
50	O
µM	O
).	O

The	O
fractional	O
change	O
in	O
anisotropy	O
,	O
ΔF	O
/	O
Fo	O
,	O
is	O
plotted	O
against	O
the	O
concentration	O
of	O
LuxR	B-GP
(	O
nM	O
).	O

B	O
.	O
Kd	O
values	O
are	O
calculated	O
as	O
the	O
half	O
-	O
maximal	O
fractional	O
change	O
in	O
fluorescence	O
anisotropy	O
in	O
the	O
absence	O
and	O
presence	O
of	O
cinnamaldehyde	O
or	O
cinnamaldehyde	O
analogs	O
.	O

Vibrio	B-OG
strains	O
used	O
in	O
this	O
study	O
.	O

Strain	O

Characteristics	O

Reference	O
/	O
source	O

V	B-OG
.	I-OG
harveyi	I-OG
BB	O
120	O

Wild	O
-	O
type	O

[	O
2	O
]	O

V	B-OG
.	I-OG
harveyi	I-OG
BB152	O

luxLM	O
::	O
Tn5	O

[	O
6	O
]	O

V	B-OG
.	I-OG
harveyi	I-OG
BB	O
170	O

luxN	B-GP
::	O
Tn5	O

[	O
1	O
]	O

V	B-OG
.	I-OG
harveyi	I-OG
MM	O
30	O

luxS	O
::	O
Tn5	O

[	O
30	O
]	O

V	B-OG
.	I-OG
harveyi	I-OG
BB886	O

luxPQ	O
::	O
Tn5	O
KanR	O

[	O
6	O
]	O

V	B-OG
.	I-OG
harveyi	I-OG
JAF	O
375	O

luxN	B-GP
::	O
CmR	O
luxQ	O
::	O
KanR	O

[	O
7	O
]	O

V	B-OG
.	I-OG
harveyi	I-OG
JMH	O
597	O

luxN	B-GP
::	O
Tn5	O
cqsS	B-GP
::	O
CmR	O

[	O
9	O
]	O

V	B-OG
.	I-OG
harveyi	I-OG
JAF	O
553	O

luxU	B-GP
H58A	O
linked	O
to	O
KanR	O

[	O
5	O
]	O

V	B-OG
.	I-OG
harveyi	I-OG
JAF	O
483	O

luxO	B-GP
D47A	O
linked	O
to	O
KanR	O

[	O
7	O
]	O

V	B-OG
.	I-OG
harveyi	I-OG
BNL	O
258	O

hfq	O
::	O
Tn5lacZ	O

[	O
31	O
]	O

V	B-OG
.	I-OG
anguillarum	I-OG
LMG	I-OG
4411	I-OG

Isolated	O
from	O
young	O
sea	B-OG
trout	I-OG
(	O
Salmo	B-OG
trutta	I-OG
)	O

BCCM	O
/	O
LMG	O

V	B-OG
.	I-OG
cholerae	I-OG
NCTC	I-OG
8457	I-OG

Isolated	O
from	O
human	B-OG
,	O
biotype	O
El	O
Tor	O

HPACC	O

V	B-OG
.	I-OG
cholerae	I-OG
CIP	I-OG
106855	I-OG

Isolated	O
from	O
human	B-OG
,	O
biotype	O
El	O
Tor	O
,	O
HapR	B-GP
frameshift	O

CIP	O

V	B-OG
.	I-OG
vulnificus	I-OG
LMG	I-OG
16867	I-OG

Isolated	O
from	O
tank	O
water	O
on	O
eel	O
farm	O

BCCM	O
/	O
LMG	O

BCCM	O
/	O
LMG	O
,	O
Belgian	O
Co	O
-	O
ordinated	O
Collections	O
/	O
Laboratory	O
of	O
Microbiology	O
collection	O
(	O
Ghent	O
University	O
,	O
Belgium	O
);	O
HPACC	O
,	O
Health	O
Protection	O
Agency	O
Culture	O
Collection	O
(	O
Salisbury	O
,	O
UK	O
);	O
CIP	O
,	O
Collection	O
of	O
Institute	O
Pasteur	O
(	O
Paris	O
,	O
France	O
).	O

Cinnamaldehyde	O
and	O
cinnamaldehyde	O
analogs	O
affect	O
the	O
in	O
vitro	O
production	O
of	O
QS	O
-	O
regulated	O
virulence	O
factors	O

Subsequently	O
we	O
evaluated	O
the	O
effect	O
of	O
the	O
selected	O
compounds	O
on	O
the	O
in	O
vitro	O
production	O
of	O
putative	O
virulence	O
factors	O
.	O

All	O
compounds	O
investigated	O
were	O
found	O
to	O
decrease	O
protease	B-GP
activity	O
in	O
Vibrio	B-OG
anguillarum	I-OG
LMG	I-OG
4411	I-OG
and	O
Vibrio	B-OG
cholerae	I-OG
NCTC	I-OG
8457	I-OG
with	O
25	O
–	O
74	O
%	O
(	O
Table	O
3	O
).	O

No	O
effects	O
were	O
observed	O
on	O
protease	B-GP
production	O
in	O
V	B-OG
.	I-OG
cholerae	I-OG
CIP	I-OG
106855	I-OG
,	O
a	O
strain	O
containing	O
a	O
non	O
-	O
functional	O
HapR	B-GP
(	O
LuxR	B-GP
homolog	O
).	O

All	O
compounds	O
were	O
found	O
to	O
decrease	O
the	O
pigment	O
production	O
in	O
V	B-OG
.	I-OG
anguillarum	I-OG
LMG	I-OG
4411	I-OG
with	O
15	O
%	O
to	O
65	O
%	O
(	O
Table	O
3	O
).	O

This	O
is	O
in	O
agreement	O
with	O
the	O
previous	O
finding	O
that	O
pigment	O
production	O
in	O
V	B-OG
.	I-OG
anguillarum	I-OG
and	O
protease	B-GP
production	O
in	O
V	B-OG
.	I-OG
anguillarum	I-OG
and	O
V	B-OG
.	I-OG
cholerae	I-OG
are	O
at	O
least	O
partially	O
controlled	O
by	O
the	O
AI	O
-	O
2	O
QS	O
system	O
[	O
8	O
],	O
[	O
10	O
],	O
[	O
13	O
].	O

Effect	O
of	O
the	O
cinnamaldehyde	O
analogs	O
(	O
100	O
µM	O
)	O
on	O
different	O
QS	O
-	O
regulated	O
phenotypes	O
.	O

Code	O
*	O

Compound	O

Protease	B-GP
activity	O

Pigment	O
production	O

V	B-OG
.	I-OG
anguillarum	I-OG

V	B-OG
.	I-OG
cholerae	I-OG

V	B-OG
.	I-OG
anguillarum	I-OG

LMG	O
4411	O

NCTC	O
8457	O

LMG	O
4411	O

1	O

Cinnamaldehyde	O

27	O
±	O
3	O

28	O
±	O
10	O

26	O
±	O
3	O

2	O

2	O
-	O
Nitro	O
-	O
cinnamaldehyde	O

39	O
±	O
13	O

27	O
±	O
8	O

36	O
±	O
1	O

9	O

3	O
,	O
4	O
-	O
Dichloro	O
-	O
cinnamaldehyde	O
**	O

47	O
±	O
17	O

62	O
±	O
12	O

28	O
±	O
5	O

22	O

(	O
E	O
)-	O
4	O
-	O
Phenyl	O
-	O
3	O
-	O
buten	O
-	O
2	O
-	O
one	O

43	O
±	O
12	O

32	O
±	O
6	O

25	O
±	O
5	O

30	O

(	O
E	O
)-	O
3	O
-	O
Decen	O
-	O
2	O
-	O
one	O

74	O
±	O
15	O

43	O
±	O
8	O

64	O
±	O
20	O

25	O

(	O
E	O
)-	O
2	O
-	O
Pentenal	O

46	O
±	O
6	O

25	O
±	O
9	O

15	O
±	O
7	O

26	O

(	O
E	O
)-	O
2	O
-	O
Nonenal	O

74	O
±	O
17	O

41	O
±	O
7	O

48	O
±	O
8	O

Biofilm	O
biomass	O

V	B-OG
.	I-OG
anguillarum	I-OG

V	B-OG
.	I-OG
cholerae	I-OG

V	B-OG
.	I-OG
anguillarum	I-OG

LMG	O
4411	O

NCTC	O
8457	O

LMG	O
4411	O

1	O

Cinnamaldehyde	O

24	O
±	O
11	O

17	O
±	O
14	O
***	O

21	O
±	O
12	O

2	O

2	O
-	O
Nitro	O
-	O
cinnamaldehyde	O

31	O
±	O
12	O

16	O
±	O
12	O
***	O

NS	O

9	O

3	O
,	O
4	O
-	O
Dichloro	O
-	O
cinnamaldehyde	O
**	O

16	O
±	O
4	O

27	O
±	O
12	O
***	O

50	O
±	O
27	O

22	O

(	O
E	O
)-	O
4	O
-	O
Phenyl	O
-	O
3	O
-	O
buten	O
-	O
2	O
-	O
one	O

34	O
±	O
9	O

18	O
±	O
11	O
***	O

14	O
±	O
9	O

30	O

(	O
E	O
)-	O
3	O
-	O
Decen	O
-	O
2	O
-	O
one	O

19	O
±	O
12	O

31	O
±	O
18	O
***	O

24	O
±	O
14	O

25	O

(	O
E	O
)-	O
2	O
-	O
Pentenal	O

19	O
±	O
11	O

NS	O

NS	O

26	O

(	O
E	O
)-	O
2	O
-	O
Nonenal	O

23	O
±	O
5	O

29	O
±	O
17	O
***	O

38	O
±	O
8	O

;	O
Code	O
refers	O
to	O
structures	O
in	O
Figure	O
1	O
.	O

Results	O
are	O
expressed	O
as	O
the	O
percentage	O
inhibition	O
compared	O
to	O
the	O
untreated	O
control	O
(±	O
SD	O
).	O

NS	O
:	O
no	O
significant	O
inhibition	O
compared	O
to	O
an	O
untreated	O
control	O
(	O
p	O
>	O
0	O
.	O
05	O
;	O
Mann	O
-	O
Whitney	O
U	O
).	O

;	O
compound	O
was	O
used	O
in	O
50	O
µM	O
concentration	O
.	O

;	O
for	O
V	B-OG
.	I-OG
cholerae	I-OG
NCTC	I-OG
8457	I-OG
results	O
are	O
expressed	O
as	O
the	O
percentage	O
increase	O
(	O
instead	O
of	O
decrease	O
)	O
in	O
biofilm	O
biomass	O
compared	O
to	O
the	O
untreated	O
control	O
.	O

No	O
effect	O
was	O
observed	O
on	O
V	B-OG
.	I-OG
cholerae	I-OG
CIP	I-OG
106855	I-OG
and	O
V	B-OG
.	I-OG
harveyi	I-OG
BB120	I-OG
biomass	O
(	O
data	O
not	O
shown	O
),	O
but	O
several	O
compounds	O
decreased	O
biofilm	O
formation	O
in	O
V	B-OG
.	I-OG
anguillarum	I-OG
LMG	I-OG
4411	I-OG
and	O
V	B-OG
.	I-OG
vulnificus	I-OG
LMG	I-OG
16867	I-OG
(	O
Table	O
3	O
).	O

However	O
,	O
when	O
using	O
a	O
resazurin	O
-	O
based	O
viability	O
assay	O
no	O
differences	O
in	O
the	O
number	O
of	O
metabolically	O
active	O
cells	O
in	O
the	O
V	B-OG
.	I-OG
harveyi	I-OG
BB120	I-OG
,	O
V	B-OG
.	I-OG
anguillarum	I-OG
LMG	I-OG
4411	I-OG
,	O
V	B-OG
.	I-OG
vulnificus	I-OG
LMG	I-OG
16867	I-OG
and	O
V	B-OG
.	I-OG
cholerae	I-OG
CIP	I-OG
106855	I-OG
biofilm	O
were	O
observed	O
(	O
data	O
not	O
shown	O
).	O

Mutations	O
in	O
the	O
LuxR	B-GP
homologues	O
of	O
V	B-OG
.	I-OG
anguillarum	I-OG
(	O
VanT	B-GP
)	O
and	O
V	B-OG
.	I-OG
vulnificus	I-OG
(	O
SmcR	B-GP
)	O
have	O
been	O
shown	O
to	O
reduce	O
biofilm	O
formation	O
,	O
suggesting	O
that	O
in	O
these	O
species	O
AI	O
-	O
2	O
QS	O
promotes	O
biofilm	O
formation	O
[	O
8	O
],	O
[	O
14	O
].	O

Our	O
data	O
support	O
the	O
hypothesis	O
that	O
cinnamaldehyde	O
and	O
selected	O
cinnamaldehyde	O
analogs	O
affect	O
biofilm	O
formation	O
by	O
inhibiting	O
matrix	O
production	O
and	O
/	O
or	O
accumulation	O
since	O
a	O
decrease	O
in	O
biomass	O
could	O
not	O
be	O
attributed	O
to	O
a	O
decrease	O
in	O
the	O
number	O
of	O
viable	O
cells	O
[	O
10	O
].	O

In	O
contrast	O
,	O
a	O
higher	O
biomass	O
was	O
found	O
for	O
V	B-OG
.	I-OG
cholerae	I-OG
NCTC	I-OG
8457	I-OG
when	O
treated	O
with	O
cinnamaldehyde	O
or	O
cinnamaldehyde	O
analogs	O
(	O
Table	O
3	O
).	O

In	O
addition	O
,	O
a	O
significantly	O
higher	O
number	O
of	O
metabolically	O
active	O
cells	O
was	O
found	O
in	O
this	O
biofilm	O
when	O
treated	O
with	O
(	O
E	O
)-	O
2	O
-	O
nonenal	O
and	O
(	O
E	O
)-	O
3	O
-	O
decen	O
-	O
2	O
-	O
one	O
(	O
127	O
±	O
14	O
%	O
and	O
114	O
±	O
9	O
%,	O
respectively	O
).	O
V	B-OG
.	I-OG
cholerae	I-OG
HapR	B-GP
has	O
been	O
shown	O
to	O
repress	O
the	O
expression	O
of	O
vps	B-GP
genes	O
(	O
involved	O
in	O
the	O
production	O
of	O
exopolysaccharides	O
)	O
and	O
biofilm	O
formation	O
,	O
indicating	O
that	O
AI	O
-	O
2	O
QS	O
negatively	O
influences	O
biofilm	O
formation	O
in	O
this	O
species	O
[	O
15	O
],	O
[	O
16	O
].	O

This	O
is	O
consistent	O
with	O
the	O
observed	O
positive	O
effects	O
in	O
this	O
study	O
of	O
AI	O
-	O
2	O
QS	O
inhibitors	O
on	O
biofilm	O
formation	O
of	O
V	B-OG
.	I-OG
cholerae	I-OG
NCTC	I-OG
8457	I-OG
,	O
while	O
no	O
effect	O
was	O
observed	O
for	O
a	O
strain	O
lacking	O
a	O
functional	O
HapR	B-GP
.	O

The	O
effect	O
of	O
the	O
selected	O
compounds	O
on	O
the	O
starvation	O
response	O
of	O
the	O
different	O
Vibrio	B-OG
spp	I-OG
.	O
was	O
also	O
investigated	O
.	O

In	O
the	O
control	O
experiments	O
no	O
decrease	O
in	O
the	O
number	O
of	O
culturable	O
cells	O
was	O
observed	O
after	O
48	O
h	O
of	O
incubation	O
(	O
data	O
not	O
shown	O
).	O

However	O
when	O
cells	O
were	O
starved	O
in	O
the	O
presence	O
of	O
one	O
of	O
the	O
seven	O
compounds	O
tested	O
,	O
significantly	O
less	O
cells	O
were	O
recovered	O
(	O
Table	O
4	O
).	O

The	O
highest	O
reductions	O
in	O
the	O
number	O
of	O
recovered	O
cells	O
was	O
observed	O
with	O
the	O
most	O
active	O
QS	O
inhibitors	O
,	O
(	O
E	O
)-	O
3	O
-	O
decen	O
-	O
2	O
-	O
one	O
,	O
3	O
,	O
4	O
-	O
dichloro	O
-	O
cinnamaldehyde	O
and	O
(	O
E	O
)-	O
2	O
-	O
nonenal	O
(	O
Table	O
4	O
).	O

Our	O
data	O
indicate	O
that	O
inhibition	O
of	O
AI	O
-	O
2	O
based	O
QS	O
suppresses	O
the	O
starvation	O
response	O
and	O
renders	O
cells	O
more	O
susceptible	O
to	O
starvation	O
-	O
associated	O
stress	O
conditions	O
.	O

A	O
correlation	O
was	O
observed	O
between	O
the	O
AI	O
-	O
2	O
QS	O
inhibitory	O
effect	O
of	O
the	O
compounds	O
and	O
their	O
effects	O
on	O
in	O
vitro	O
production	O
of	O
virulence	O
factors	O
.	O

Effect	O
of	O
the	O
QS	O
inhibitors	O
on	O
the	O
QS	O
regulated	O
starvation	O
response	O
(	O
data	O
are	O
presented	O
as	O
average	O
log	O
reduction	O
in	O
CFU	O
/	O
ml	O
after	O
48	O
h	O
compared	O
to	O
an	O
untreated	O
control	O
).	O

Code	O
*	O

Compounds	O

Average	O
log	O
reduction	O
CFU	O
/	O
ml	O
(±	O
SD	O
)	O

V	B-OG
.	I-OG
anguillarum	I-OG

V	B-OG
.	I-OG
cholerae	I-OG

V	B-OG
.	I-OG
harveyi	I-OG

V	B-OG
.	I-OG
vulnificus	I-OG

LMG	O
4411	O

NCTC	O
8457	O

BB120	O

LMG	O
16867	O

1	O

Cinnamaldehyde	O

1	O
.	O
15	O
±	O
0	O
.	O
56	O

NS	O

NS	O

NS	O

2	O

2	O
-	O
Nitro	O
-	O
cinnamaldehyde	O

1	O
.	O
14	O
±	O
0	O
.	O
32	O

1	O
.	O
33	O
±	O
0	O
.	O
22	O

NS	O

NS	O

9	O

3	O
,	O
4	O
-	O
Dichloro	O
-	O
cinnamaldehyde	O

>	O
6	O
.	O
60	O
***	O

>	O
6	O
.	O
83	O
***	O

5	O
.	O
99	O
±	O
0	O
.	O
66	O

3	O
.	O
88	O
±	O
0	O
.	O
40	O

22	O

(	O
E	O
)-	O
4	O
-	O
Phenyl	O
-	O
3	O
-	O
buten	O
-	O
2	O
-	O
one	O

0	O
.	O
81	O
±	O
0	O
.	O
25	O

NS	O

NS	O

NS	O

30	O

(	O
E	O
)-	O
3	O
-	O
Decen	O
-	O
2	O
-	O
one	O

2	O
.	O
76	O
±	O
0	O
.	O
44	O

3	O
.	O
29	O
±	O
0	O
.	O
27	O

5	O
.	O
34	O
±	O
0	O
.	O
41	O

1	O
.	O
48	O
±	O
0	O
.	O
17	O

25	O

(	O
E	O
)-	O
2	O
-	O
Pentenal	O

1	O
.	O
08	O
±	O
0	O
.	O
16	O

1	O
.	O
35	O
±	O
0	O
.	O
16	O

2	O
.	O
40	O
±	O
0	O
.	O
78	O

NS	O

26	O

(	O
E	O
)-	O
2	O
-	O
Nonenal	O
**	O

>	O
6	O
.	O
60	O
***	O

2	O
.	O
64	O
±	O
0	O
.	O
54	O

>	O
6	O
.	O
94	O
***	O

2	O
.	O
46	O
±	O
0	O
.	O
48	O

;	O
Code	O
refers	O
to	O
structures	O
in	O
Figure	O
1	O
.	O

Compounds	O
were	O
used	O
at	O
100	O
µM	O
concentrations	O
,	O
except	O
3	O
,	O
4	O
-	O
dichloro	O
-	O
cinnamaldehyde	O
(	O
50	O
µM	O
).	O

NS	O
:	O
not	O
significantly	O
different	O
from	O
an	O
untreated	O
control	O
(	O
p	O
>	O
0	O
.	O
05	O
;	O
Mann	O
-	O
Whitney	O
U	O
).	O

;	O
50	O
µM	O
was	O
used	O
for	O
V	B-OG
.	I-OG
cholerae	I-OG
NCTC	I-OG
8457	I-OG
.	O

;	O
No	O
recovery	O
of	O
cells	O
after	O
48	O
h	O
(	O
i	O
.	O
e	O
.	O
<	O
20	O
cells	O
/	O
ml	O
survived	O
starvation	O
).	O

Cinnamaldehyde	O
and	O
cinnamaldehyde	O
analogs	O
affect	O
virulence	O
of	O
Vibrio	B-OG
spp	I-OG
.	O
in	O
C	B-OG
.	I-OG
elegans	I-OG

To	O
investigate	O
the	O
effect	O
of	O
the	O
different	O
compounds	O
on	O
virulence	O
in	O
vivo	O
,	O
C	B-OG
.	I-OG
elegans	I-OG
nematodes	B-OG
were	O
infected	O
with	O
various	O
Vibrio	B-OG
strains	O
in	O
the	O
presence	O
and	O
absence	O
of	O
selected	O
cinnamaldehyde	O
analogs	O
.	O

Five	O
selected	O
compounds	O
were	O
found	O
to	O
be	O
non	O
-	O
toxic	O
towards	O
C	B-OG
.	I-OG
elegans	I-OG
when	O
used	O
at	O
100	O
µM	O
.	O

3	O
,	O
4	O
-	O
Di	O
-	O
chloro	O
-	O
cinnamaldehyde	O
and	O
2	O
-	O
nitro	O
-	O
cinnamaldehyde	O
were	O
toxic	O
in	O
concentrations	O
above	O
25	O
µM	O
and	O
,	O
hence	O
were	O
used	O
in	O
concentrations	O
below	O
this	O
threshold	O
.	O

In	O
the	O
absence	O
of	O
QS	O
inhibitors	O
,	O
only	O
71	O
±	O
4	O
%,	O
49	O
±	O
13	O
%	O
and	O
15	O
±	O
13	O
%	O
of	O
the	O
nematodes	B-OG
infected	O
with	O
V	B-OG
.	I-OG
anguillarum	I-OG
LMG	I-OG
4411	I-OG
,	O
V	B-OG
.	I-OG
harveyi	I-OG
BB120	I-OG
and	O
V	B-OG
.	I-OG
vulnificus	I-OG
LMG	I-OG
16867	I-OG
respectively	O
,	O
survived	O
48	O
h	O
post	O
infection	B-DS
.	O

All	O
QS	O
inhibitors	O
significantly	O
increased	O
survival	O
after	O
infection	B-DS
,	O
with	O
the	O
most	O
pronounced	O
effect	O
observed	O
for	O
3	O
,	O
4	O
-	O
dichloro	O
-	O
cinnamaldehyde	O
(	O
Fig	O
.	O
3	O
).	O

No	O
differences	O
in	O
survival	O
were	O
observed	O
when	O
C	B-OG
.	I-OG
elegans	I-OG
was	O
treated	O
with	O
the	O
different	O
compounds	O
after	O
infection	B-DS
with	O
V	B-OG
.	I-OG
cholerae	I-OG
NCTC	I-OG
8457	I-OG
(	O
data	O
not	O
shown	O
).	O

Survival	O
curves	O
after	O
infection	B-DS
of	O
C	B-OG
.	I-OG
elegans	I-OG
with	O
V	B-OG
.	I-OG
anguillarum	I-OG
LMG	I-OG
4411	I-OG
,	O
V	B-OG
.	I-OG
harveyi	I-OG
BB120	I-OG
or	O
V	B-OG
.	I-OG
vulnificus	I-OG
LMG	I-OG
16867	I-OG
in	O
the	O
presence	O
or	O
absence	O
of	O
QS	O
inhibitors	O
.	O

Structure	O
-	O
activity	O
relationship	O
of	O
cinnamaldehyde	O
and	O
cinnamaldehyde	O
analogs	O
suggest	O
that	O
a	O
Michael	O
-	O
type	O
addition	O
to	O
LuxR	B-GP
residues	O
is	O
important	O
for	O
activity	O

Based	O
on	O
our	O
observations	O
,	O
we	O
hypothesized	O
that	O
cinnamaldehyde	O
binds	O
as	O
a	O
ligand	O
to	O
LuxR	B-GP
,	O
thereby	O
changing	O
the	O
latters	O
conformation	O
and	O
consequently	O
decreasing	O
its	O
ability	O
to	O
bind	O
to	O
DNA	O
.	O
α	O
,	O
β	O
unsaturated	O
carbonyl	O
compounds	O
can	O
react	O
with	O
nucleophiles	O
,	O
in	O
a	O
Michael	O
-	O
type	O
addition	O
reaction	O
.	O

In	O
this	O
way	O
,	O
nucleophilic	O
amino	O
acid	O
side	O
chains	O
(	O
e	O
.	O
g	O
.	O
the	O
thiol	O
groups	O
of	O
cysteine	O
residues	O
)	O
in	O
LuxR	B-GP
possibly	O
react	O
with	O
the	O
electrophilic	O
β	O
-	O
position	O
to	O
form	O
irreversible	O
cinnamaldehyde	O
-	O
receptor	O
conjugates	O
.	O

This	O
would	O
yield	O
a	O
modified	O
protein	O
,	O
likely	O
resulting	O
in	O
a	O
reduced	O
ability	O
to	O
bind	O
to	O
DNA	O
.	O

Compounds	O
capable	O
of	O
participating	O
in	O
a	O
Michael	O
-	O
type	O
addition	O
reaction	O
were	O
found	O
to	O
be	O
active	O
,	O
while	O
replacement	O
of	O
the	O
aldehyde	O
group	O
by	O
a	O
carboxylic	O
acid	O
moiety	O
resulted	O
in	O
less	O
active	O
compounds	O
.	O

Compounds	O
lacking	O
the	O
double	O
bond	O
were	O
found	O
to	O
be	O
inactive	O
(	O
e	O
.	O
g	O
.	O
3	O
-	O
phenylpropionaldehyde	O
and	O
4	O
-	O
phenyl	O
-	O
2	O
-	O
butanone	O
)	O
(	O
Fig	O
.	O
1	O
;	O
Table	O
1	O
).	O

Vinyl	O
sulfone	O
(	O
e	O
.	O
g	O
.	O
methyl	O
-	O
styryl	O
sulfone	O
)	O
polarizes	O
the	O
double	O
bond	O
more	O
than	O
the	O
corresponding	O
vinyl	O
aldehyde	O
,	O
and	O
thus	O
it	O
is	O
no	O
surprise	O
that	O
replacement	O
of	O
the	O
vinyl	O
aldehyde	O
function	O
by	O
a	O
vinyl	O
sulfone	O
leads	O
to	O
a	O
more	O
active	O
compound	O
.	O

These	O
data	O
strongly	O
suggest	O
the	O
involvement	O
of	O
a	O
Michael	O
-	O
type	O
addition	O
reaction	O
.	O

The	O
QS	O
inhibitory	O
effect	O
of	O
cinnamaldehyde	O
analogs	O
was	O
also	O
highly	O
dependent	O
on	O
the	O
nature	O
and	O
degree	O
of	O
substitution	O
of	O
the	O
aromatic	O
ring	O
.	O

In	O
general	O
,	O
substituents	O
with	O
electron	O
withdrawing	O
properties	O
increased	O
activity	O
.	O

Examination	O
of	O
the	O
physiochemical	O
properties	O
including	O
electronic	O
(	O
Hammett	O
sigma	O
constant	O
,	O
σ	O
)	O
and	O
lipophilic	O
properties	O
(	O
the	O
Hansch	O
constant	O
,	O
π	O
)	O
further	O
indicated	O
that	O
substitutions	O
yielding	O
higher	O
π	O
+	O
σ	O
values	O
resulted	O
in	O
increased	O
inhibition	O
.	O

The	O
inhibitory	O
activity	O
decreased	O
in	O
the	O
order	O
3	O
,	O
4	O
-	O
dichloro	O
-	O
cinnamaldehyde	O
(	O
9	O
)/	O
4	O
-	O
chloro	O
-	O
3	O
-	O
trifluoromethyl	O
-	O
cinnamaldehyde	O
(	O
14	O
)	O
>	O
4	O
-	O
chloro	O
-	O
cinnamaldehyde	O
(	O
10	O
)	O
>	O
cinnamaldehyde	O
(	O
1	O
).	O

Although	O
4	O
-	O
trifluoromethyl	O
-	O
cinnamaldehyde	O
(	O
7	O
)	O
has	O
the	O
same	O
σ	O
value	O
as	O
3	O
,	O
4	O
-	O
dichloro	O
-	O
cinnamaldehyde	O
(	O
9	O
),	O
its	O
lower	O
inhibitory	O
activity	O
is	O
likely	O
due	O
to	O
its	O
lower	O
hydrophobicity	O
and	O
the	O
lack	O
of	O
a	O
meta	O
-	O
sterical	O
effect	O
[	O
17	O
]-[	O
18	O
].	O

In	O
addition	O
,	O
4	O
-	O
nitro	O
-	O
cinnamaldehyde	O
(	O
3	O
)	O
has	O
a	O
lower	O
activity	O
than	O
3	O
,	O
4	O
-	O
dichloro	O
-	O
cinnamaldehyde	O
(	O
9	O
)	O
indicating	O
that	O
a	O
favourable	O
σ	O
value	O
can	O
be	O
neutralised	O
by	O
an	O
unfavourable	O
π	O
effect	O
.	O

Recently	O
,	O
the	O
crystal	O
structure	O
of	O
two	O
LuxR	B-GP
homologues	O
,	O
SmcR	B-GP
in	O
V	B-OG
.	I-OG
vulnificus	I-OG
and	O
HapR	B-GP
in	O
V	B-OG
.	I-OG
cholerae	I-OG
,	O
was	O
described	O
[	O
19	O
]–[	O
20	O
].	O

Both	O
proteins	O
show	O
conserved	O
putative	O
ligand	O
-	O
binding	O
sites	O
which	O
are	O
surrounded	O
by	O
polar	O
amino	O
acids	O
side	O
chains	O
on	O
one	O
side	O
of	O
the	O
pocket	O
and	O
by	O
hydrophobic	O
residues	O
on	O
the	O
other	O
side	O
[	O
19	O
].	O

Further	O
analysis	O
revealed	O
a	O
positive	O
charge	O
in	O
the	O
pocket	O
[	O
20	O
].	O

These	O
results	O
indicate	O
that	O
for	O
optimal	O
binding	O
affinity	O
a	O
ligand	O
should	O
contain	O
a	O
hydrophobic	O
side	O
chain	O
as	O
well	O
as	O
a	O
(	O
partially	O
)	O
negative	O
charge	O
.	O

Although	O
no	O
small	O
molecule	O
ligands	O
which	O
fit	O
these	O
pockets	O
have	O
been	O
identified	O
so	O
far	O
,	O
the	O
amphipatic	O
nature	O
of	O
cinnamaldehyde	O
suggests	O
that	O
it	O
might	O
act	O
as	O
a	O
LuxR	B-GP
-	O
ligand	O
,	O
thereby	O
changing	O
the	O
DNA	O
-	O
binding	O
ability	O
of	O
LuxR	B-GP
.	O

However	O
,	O
in	O
order	O
to	O
gather	O
additional	O
support	O
for	O
this	O
proposed	O
mechanism	O
and	O
in	O
order	O
to	O
identify	O
the	O
site	O
(	O
s	O
)	O
of	O
modification	O
in	O
LuxR	B-GP
by	O
cinnamaldehyde	O
or	O
cinnamaldehyde	O
analogs	O
,	O
the	O
protein	O
-	O
inhibitor	O
complex	O
should	O
be	O
investigated	O
.	O

Unfortunately	O
,	O
the	O
currently	O
available	O
overexpression	O
construct	O
(	O
GST	B-GP
-	O
LuxR	B-GP
)	O
[	O
12	O
]	O
does	O
not	O
allow	O
to	O
purify	O
LuxR	B-GP
in	O
sufficient	O
quantities	O
to	O
permit	O
analyzing	O
the	O
protein	O
-	O
inhibitor	O
complex	O
by	O
X	O
-	O
ray	O
crystallography	O
or	O
by	O
MALDI	O
-	O
MS	O
(	O
data	O
not	O
shown	O
).	O

The	O
active	O
AI	O
-	O
2	O
inhibiting	O
cinnamaldehyde	O
analogs	O
have	O
drug	O
-	O
like	O
properties	O

In	O
order	O
to	O
be	O
potentially	O
useful	O
as	O
therapeutic	O
agents	O
,	O
active	O
molecules	O
need	O
to	O
satisfy	O
several	O
criteria	O
.	O

The	O
topological	O
polar	O
surface	O
area	O
(	O
TPSA	O
)	O
is	O
,	O
together	O
with	O
the	O
molecular	O
volume	O
,	O
lipophilicity	O
and	O
solubility	O
,	O
widely	O
acknowledged	O
as	O
an	O
important	O
factor	O
determining	O
transport	O
of	O
drugs	O
across	O
membranes	O
.	O

It	O
has	O
been	O
suggested	O
that	O
passively	O
absorbed	O
compounds	O
should	O
have	O
a	O
maximum	O
TPSA	O
of	O
120	O
Å2	O
.	O

In	O
addition	O
,	O
there	O
is	O
reasonable	O
probability	O
that	O
compounds	O
are	O
well	O
absorbed	O
when	O
they	O
have	O
logP	O
(	O
octanol	O
/	O
water	O
partition	O
coefficient	O
)	O
values	O
below	O
5	O
.	O
0	O
.	O

All	O
compounds	O
used	O
have	O
a	O
TPSA	O
below	O
120	O
Å2	O
(	O
Supplementary	O
Table	O
S1	O
).	O

In	O
addition	O
,	O
the	O
most	O
active	O
AI	O
-	O
2	O
QS	O
inhibitors	O
all	O
have	O
a	O
logP	O
value	O
above	O
2	O
and	O
a	O
molecular	O
volume	O
of	O
130	O
–	O
150	O
Å3	O
(	O
Supplementary	O
Table	O
S1	O
).	O

All	O
compounds	O
were	O
further	O
evaluated	O
for	O
compliance	O
with	O
Lipinski	O
'	O
s	O
‘	O
rule	O
-	O
of	O
-	O
five	O
’	O
[	O
21	O
].	O

This	O
rule	O
summarizes	O
important	O
molecular	O
pharmacokinetic	O
properties	O
of	O
a	O
compound	O
that	O
make	O
it	O
potentially	O
applicable	O
as	O
an	O
oral	O
drug	O
.	O

Most	O
drug	O
-	O
like	O
molecules	O
have	O
logP	O
<	O
5	O
,	O
molecular	O
weight	O
<	O
500	O
and	O
should	O
contain	O
not	O
more	O
than	O
10	O
hydrogen	O
bond	O
acceptors	O
and	O
less	O
than	O
5	O
hydrogen	O
bond	O
donors	O
.	O

None	O
of	O
the	O
most	O
active	O
QS	O
inhibiting	O
compounds	O
violated	O
this	O
‘	O
rule	O
-	O
of	O
-	O
five	O
’.	O

However	O
,	O
these	O
compounds	O
are	O
likely	O
to	O
react	O
irreversibly	O
with	O
different	O
proteins	O
,	O
a	O
property	O
that	O
is	O
preferably	O
avoided	O
in	O
drug	O
development	O
.	O

The	O
cytotoxicity	O
of	O
the	O
most	O
promising	O
compounds	O
,	O
3	O
,	O
4	O
-	O
dichloro	O
-	O
cinnamaldehyde	O
(	O
9	O
),	O
(	O
E	O
)-	O
2	O
-	O
nonenal	O
(	O
26	O
)	O
and	O
(	O
E	O
)-	O
3	O
-	O
decen	O
-	O
2	O
-	O
one	O
(	O
30	O
)	O
was	O
evaluated	O
against	O
MRC	O
-	O
5	O
cells	O
.	O

An	O
IC50	O
value	O
of	O
22	O
±	O
1	O
µM	O
was	O
found	O
for	O
3	O
,	O
4	O
-	O
dichloro	O
-	O
cinnamaldehyde	O
(	O
9	O
).	O

This	O
result	O
is	O
in	O
agreement	O
with	O
the	O
observed	O
toxicity	O
of	O
this	O
compound	O
towards	O
C	B-OG
.	I-OG
elegans	I-OG
.	O

In	O
contrast	O
,	O
IC50	O
values	O
for	O
cinnamaldehyde	O
(	O
1	O
),	O
(	O
E	O
)-	O
3	O
-	O
decen	O
-	O
2	O
-	O
one	O
(	O
30	O
)	O
and	O
(	O
E	O
)-	O
2	O
-	O
nonenal	O
(	O
26	O
)	O
were	O
much	O
higher	O
(	O
77	O
±	O
22	O
µM	O
,	O
>	O
640	O
µM	O
and	O
192	O
±	O
97	O
µM	O
,	O
respectively	O
).	O

In	O
addition	O
,	O
(	O
E	O
)-	O
2	O
-	O
nonenal	O
(	O
26	O
)	O
and	O
(	O
E	O
)-	O
3	O
-	O
decen	O
-	O
2	O
-	O
one	O
(	O
30	O
)	O
proved	O
active	O
blockers	O
of	O
in	O
vivo	O
virulence	O
at	O
low	O
micromolar	O
concentrations	O
(	O
even	O
sub	O
-	O
micromolar	O
for	O
3	O
,	O
4	O
-	O
dichloro	O
-	O
cinnamaldehyde	O
),	O
which	O
suggests	O
that	O
the	O
therapeutic	O
window	O
of	O
these	O
compounds	O
is	O
high	O
enough	O
for	O
therapeutic	O
applications	O
in	O
humans	B-OG
and	O
animals	B-OG
.	O

Conclusion	O

By	O
evaluating	O
the	O
effect	O
of	O
several	O
cinnamaldehyde	O
analogs	O
on	O
AI	O
-	O
2	O
QS	O
,	O
structural	O
elements	O
important	O
for	O
AI	O
-	O
2	O
QS	O
inhibitors	O
could	O
be	O
identified	O
.	O

These	O
structural	O
elements	O
consist	O
of	O
an	O
α	O
,	O
β	O
unsaturated	O
side	O
chain	O
capable	O
of	O
reacting	O
through	O
Michael	O
addition	O
,	O
a	O
hydrophobic	O
moiety	O
as	O
well	O
as	O
a	O
(	O
partially	O
)	O
negative	O
charge	O
.	O

Although	O
no	O
small	O
molecule	O
ligands	O
for	O
LuxR	B-GP
have	O
been	O
identified	O
so	O
far	O
,	O
the	O
chemical	O
structure	O
of	O
cinnamaldehyde	O
analogs	O
and	O
their	O
effect	O
on	O
the	O
DNA	O
binding	O
ability	O
of	O
LuxR	B-GP
led	O
us	O
to	O
the	O
hypothesis	O
that	O
cinnamaldehyde	O
analogs	O
can	O
act	O
as	O
LuxR	B-GP
-	O
ligands	O
,	O
thereby	O
changing	O
the	O
DNA	O
-	O
binding	O
ability	O
of	O
LuxR	B-GP
.	O

In	O
addition	O
,	O
the	O
most	O
active	O
cinnamaldehyde	O
analogs	O
were	O
found	O
to	O
reduce	O
the	O
Vibrio	B-OG
species	O
starvation	O
response	O
,	O
to	O
affect	O
biofilm	O
formation	O
in	O
V	B-OG
.	I-OG
anguillarum	I-OG
,	O
V	B-OG
.	I-OG
vulnificus	I-OG
and	O
V	B-OG
.	I-OG
cholerae	I-OG
,	O
to	O
reduce	O
pigment	O
production	O
in	O
V	B-OG
.	I-OG
anguillarum	I-OG
and	O
protease	B-GP
production	O
in	O
V	B-OG
.	I-OG
anguillarum	I-OG
and	O
V	B-OG
.	I-OG
cholerae	I-OG
,	O
and	O
to	O
increase	O
the	O
survival	O
of	O
C	B-OG
.	I-OG
elegans	I-OG
nematodes	B-OG
infected	O
with	O
V	B-OG
.	I-OG
anguillarum	I-OG
,	O
V	B-OG
.	I-OG
harveyi	I-OG
and	O
V	B-OG
.	I-OG
vulnificus	I-OG
.	O
Finally	O
,	O
the	O
most	O
promising	O
compounds	O
have	O
drug	O
-	O
like	O
properties	O
and	O
exhibited	O
only	O
low	O
cytotoxicity	O
towards	O
a	O
MRC	O
-	O
5	O
cell	O
line	O
.	O

Materials	O
and	O
Methods	O

Cinnamaldehyde	O
and	O
analogs	O

Cinnamaldehyde	O
(	O
1	O
),	O
methyl	O
-	O
styryl	O
sulfone	O
(	O
15	O
),	O
3	O
-	O
phenylpropionaldehyde	O
(	O
16	O
),	O
3	O
-	O
phenylpropionic	O
acid	O
(	O
17	O
),	O
cinnamamide	O
(	O
18	O
),	O
cinnamic	O
acid	O
(	O
19	O
),	O
cinnamyl	O
alcohol	O
(	O
20	O
),	O
methyl	O
cinnamate	O
(	O
21	O
),	O
(	O
E	O
)-	O
4	O
-	O
phenyl	O
-	O
3	O
-	O
buten	O
-	O
2	O
-	O
one	O
(	O
22	O
),	O
4	O
-	O
phenyl	O
-	O
2	O
-	O
butanone	O
(	O
23	O
),	O
1	O
-	O
acetyl	O
-	O
1	O
-	O
cyclohexene	O
(	O
24	O
),	O
(	O
E	O
)-	O
2	O
-	O
pentenal	O
(	O
25	O
),	O
(	O
E	O
)-	O
2	O
-	O
nonenal	O
(	O
26	O
),	O
(	O
E	O
)-	O
2	O
-	O
tridecenal	O
(	O
27	O
),	O
methyl	O
-(	O
E	O
)-	O
2	O
-	O
nonenoate	O
(	O
28	O
),	O
2	O
-	O
pentenoic	O
acid	O
(	O
29	O
),	O
(	O
E	O
)-	O
3	O
-	O
decen	O
-	O
2	O
-	O
one	O
(	O
30	O
),	O
(	O
E	O
)-	O
3	O
-	O
nonen	O
-	O
2	O
-	O
one	O
(	O
31	O
),	O
5	O
-	O
methyl	O
-	O
2	O
-	O
hepten	O
-	O
4	O
-	O
one	O
(	O
32	O
),	O
(	O
E	O
)-	O
2	O
-	O
nonen	O
-	O
1	O
-	O
ol	O
(	O
33	O
),	O
(	O
E	O
)-	O
2	O
-	O
hexen	O
-	O
1	O
-	O
al	O
(	O
34	O
),	O
(	O
E	O
)-	O
2	O
-	O
heptenal	O
(	O
35	O
),	O
(	O
E	O
)-	O
3	O
-	O
octen	O
-	O
2	O
-	O
one	O
(	O
36	O
),	O
(	O
E	O
)-	O
2	O
-	O
octenal	O
(	O
37	O
),	O
2	O
-	O
octenoic	O
acid	O
(	O
38	O
),	O
(	O
E	O
)-	O
2	O
-	O
decenal	O
(	O
39	O
),	O
(	O
E	O
)-	O
2	O
-	O
undecenal	O
(	O
40	O
)	O
and	O
(	O
E	O
)-	O
2	O
-	O
dodecenal	O
(	O
41	O
)	O
were	O
obtained	O
from	O
Sigma	O
-	O
Aldrich	O
(	O
Bornem	O
,	O
Belgium	O
).	O

2	O
-	O
Methoxy	O
-	O
cinnamaldehyde	O
(	O
4	O
)	O
was	O
obtained	O
from	O
Wako	O
Pure	O
Chemical	O
Industries	O
(	O
Osaka	O
,	O
Japan	O
).	O

4	O
-	O
Methoxy	O
-	O
cinnamaldehyde	O
(	O
5	O
)	O
was	O
obtained	O
from	O
VWR	O
International	O
(	O
West	O
Chester	O
,	O
PA	O
,	O
USA	O
)	O
and	O
2	O
-	O
nitro	O
-	O
cinnamaldehyde	O
(	O
2	O
),	O
4	O
-	O
nitro	O
-	O
cinnamaldehyde	O
(	O
3	O
),	O
4	O
-	O
dimethylamino	O
-	O
cinnamaldehyde	O
(	O
6	O
),	O
4	O
-	O
trifluoromethyl	O
-	O
cinnamic	O
acid	O
(	O
8	O
),	O
4	O
-	O
chloro	O
-	O
cinnamic	O
acid	O
(	O
11	O
)	O
and	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
-	O
pentafluoro	O
-	O
cinnamic	O
acid	O
(	O
13	O
)	O
were	O
obtained	O
from	O
Acros	O
Organics	O
(	O
Geel	O
,	O
Belgium	O
).	O

4	O
-	O
Chloro	O
-	O
cinnamaldehyde	O
(	O
10	O
)	O
and	O
4	O
-	O
chloro	O
-	O
3	O
-	O
trifluoromethyl	O
-	O
cinnamaldehyde	O
(	O
14	O
)	O
were	O
synthesized	O
via	O
a	O
Wittig	O
reaction	O
as	O
previously	O
described	O
[	O
22	O
].	O

The	O
halogenated	O
cinnamaldehyde	O
analog	O
3	O
,	O
4	O
-	O
dichloro	O
-	O
cinnamaldehyde	O
(	O
9	O
)	O
was	O
synthesized	O
as	O
previously	O
described	O
[	O
23	O
].	O

The	O
halogenated	O
cinnamaldehyde	O
analogs	O
4	O
-	O
trifluoromethyl	O
-	O
cinnamaldehyde	O
(	O
7	O
)	O
and	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
-	O
pentafluoro	O
-	O
cinnamaldehyde	O
(	O
12	O
)	O
were	O
synthesized	O
by	O
conversion	O
of	O
the	O
corresponding	O
cinnamic	O
acid	O
analogs	O
into	O
acid	O
chlorides	O
and	O
subsequent	O
reduction	O
with	O
lithium	O
tri	O
-	O
tert	O
-	O
butoxyaluminiumhydride	O
[	O
24	O
].	O

Stock	O
solutions	O
of	O
all	O
compounds	O
were	O
stored	O
at	O
−	O
20	O
°	O
C	O
.	O

Bacterial	O
strains	O
,	O
nematodes	B-OG
and	O
growth	O
media	O

All	O
Vibrio	B-OG
strains	O
(	O
Table	O
2	O
)	O
were	O
routinely	O
cultured	O
overnight	O
in	O
Marine	O
Broth	O
(	O
MB	O
)	O
(	O
BD	O
,	O
Sparks	O
,	O
MD	O
,	O
USA	O
)	O
at	O
30	O
°	O
C	O
on	O
a	O
rotary	O
shaker	O
.	O
E	B-OG
.	I-OG
coli	I-OG
BL21	I-OG
pGET	O
-	O
1	O
(	O
containing	O
the	O
gst	B-GP
-	O
luxR	B-GP
overexpression	O
construct	O
)	O
and	O
E	B-OG
.	I-OG
coli	I-OG
DH5α	I-OG
pBlueLux	O
(	O
containing	O
pBluelux	O
polylinker	O
and	O
luxCDABE	O
genes	O
)	O
were	O
grown	O
in	O
Luria	O
-	O
Bertani	O
broth	O
with	O
aeration	O
at	O
37	O
°	O
C	O
in	O
the	O
presence	O
of	O
ampicillin	O
(	O
100	O
µg	O
/	O
ml	O
).	O
E	B-OG
.	I-OG
coli	I-OG
OP50	I-OG
was	O
routinely	O
cultured	O
in	O
TSB	O
at	O
37	O
°	O
C	O
.	O

C	B-OG
.	I-OG
elegans	I-OG
N2	I-OG
(	O
glp	B-GP
-	I-GP
4	I-GP
;	O
sek	B-GP
-	I-GP
1	I-GP
)	O
was	O
propagated	O
on	O
nematode	B-OG
growth	O
agar	O
(	O
0	O
.	O
25	O
%	O
peptone	B-GP
,	O
0	O
.	O
3	O
%	O
NaCl	O
,	O
1	O
.	O
7	O
%	O
agar	O
,	O
5	O
mg	O
cholesterol	O
,	O
1	O
mM	O
CaCl2	O
,	O
1	O
mM	O
MgSO4	O
,	O
25	O
mM	O
phosphate	O
buffer	O
)	O
containing	O
100	O
µg	O
/	O
ml	O
kanamycin	O
and	O
with	O
E	B-OG
.	I-OG
coli	I-OG
OP50	I-OG
as	O
a	O
food	O
source	O
.	O
C	B-OG
.	I-OG
elegans	I-OG
adults	O
were	O
harvested	O
as	O
previously	O
described	O
[	O
25	O
].	O

Determination	O
of	O
the	O
minimal	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O

MICs	O
were	O
determined	O
for	O
each	O
compound	O
and	O
strain	O
as	O
described	O
previously	O
[	O
26	O
].	O

In	O
brief	O
,	O
a	O
microdilution	O
assay	O
in	O
flat	O
bottomed	O
96	O
-	O
well	O
microtiter	O
plates	O
(	O
TPP	O
,	O
Trasadingen	O
,	O
Switzerland	O
),	O
using	O
MB	O
as	O
a	O
medium	O
was	O
used	O
.	O

The	O
plates	O
were	O
incubated	O
for	O
24	O
h	O
at	O
30	O
°	O
C	O
and	O
the	O
absorption	O
at	O
590	O
nm	O
was	O
measured	O
using	O
a	O
Victor	O
Wallac2	O
multilabel	O
counter	O
(	O
Perkin	O
Elmer	O
Life	O
and	O
Analytical	O
Sciences	O
,	O
Boston	O
,	O
MA	O
,	O
USA	O
).	O

In	O
addition	O
,	O
MIC	O
values	O
were	O
also	O
determined	O
for	O
pathogens	O
employing	O
an	O
AI	O
-	O
2	O
mediated	O
QS	O
system	O
.	O

These	O
pathogens	O
are	O
Escherichia	B-OG
coli	I-OG
BW	I-OG
25113	I-OG
,	O
E	B-OG
.	I-OG
coli	I-OG
K12	I-OG
,	O
E	B-OG
.	I-OG
coli	I-OG
LMG	I-OG
25922	I-OG
;	O
Salmonella	B-OG
enterica	I-OG
serovar	I-OG
Typhimurium	I-OG
ATCC	I-OG
700720	I-OG
,	O
Staphylococcus	B-OG
aureus	I-OG
LMG	I-OG
10147	I-OG
and	O
S	B-OG
.	I-OG
aureus	I-OG
Mu50	I-OG
.	O

When	O
used	O
in	O
concentrations	O
up	O
to	O
1000	O
µM	O
,	O
cinnamaldehyde	O
and	O
most	O
cinnamaldehyde	O
analogs	O
did	O
not	O
affect	O
the	O
growth	O
of	O
the	O
different	O
strains	O
(	O
with	O
the	O
exception	O
of	O
3	O
,	O
4	O
-	O
dichloro	O
-	O
cinnamaldehyde	O
,	O
MIC	O
≥	O
250	O
µM	O
).	O

Bioluminescence	O
assays	O

The	O
assay	O
for	O
the	O
effect	O
on	O
constitutively	O
expressed	O
bioluminescence	O
(	O
using	O
E	B-OG
.	I-OG
coli	I-OG
DH5α	I-OG
pBlueLux	O
containing	O
the	O
luxCDABE	O
genes	O
)	O
and	O
the	O
bioassay	O
to	O
determine	O
the	O
molecular	O
target	O
of	O
the	O
compounds	O
tested	O
(	O
using	O
V	B-OG
.	I-OG
harveyi	I-OG
BB120	I-OG
,	O
BB152	O
,	O
BB170	O
,	O
BB886	O
,	O
BNL258	O
,	O
JAF375	O
,	O
JAF553	O
,	O
JAF483	O
,	O
JMH597	O
and	O
MM30	O
)	O
were	O
conducted	O
as	O
described	O
previously	O
[	O
27	O
].	O

Each	O
compound	O
was	O
tested	O
at	O
least	O
six	O
times	O
in	O
triplicate	O
(	O
n	O
≥	O
18	O
).	O

Inhibitory	O
effects	O
on	O
AI	O
-	O
2	O
QS	O
were	O
assessed	O
using	O
a	O
V	B-OG
.	I-OG
harveyi	I-OG
BB170	I-OG
assay	O
[	O
10	O
].	O

Each	O
compound	O
was	O
tested	O
twelve	O
times	O
in	O
each	O
assay	O
and	O
each	O
assay	O
was	O
repeated	O
at	O
least	O
four	O
times	O
(	O
n	O
≥	O
48	O
).	O

LuxR	B-GP
-	O
DNA	O
binding	O
assay	O

Induction	O
of	O
GST	B-GP
-	O
LuxR	B-GP
overexpression	O
and	O
protein	O
purification	O
were	O
conducted	O
as	O
previously	O
described	O
[	O
12	O
].	O

GST	B-GP
-	O
LuxR	B-GP
was	O
purified	O
using	O
Glutathione	O
Uniflow	O
resins	O
(	O
Clontech	O
,	O
Mountain	O
view	O
,	O
CA	O
,	O
USA	O
)	O
and	O
fractions	O
containing	O
GST	B-GP
-	O
LuxR	B-GP
were	O
identified	O
by	O
both	O
SDS	O
-	O
PAGE	O
and	O
capillary	O
electrophoresis	O
(	O
Experion	O
PRO260	O
chip	O
;	O
Bio	O
-	O
rad	O
laboratories	O
,	O
Nazareth	O
Eke	O
,	O
Belgium	O
).	O

5	O
′	O
fluorescein	O
-	O
labelled	O
DNA	O
oligonucleotide	O
(	O
TATTGATAAATTTATCAATAA	O
)	O
and	O
its	O
unlabelled	O
complement	O
were	O
obtained	O
from	O
Sigma	O
-	O
Aldrich	O
.	O

Annealing	O
of	O
the	O
complementary	O
oligonucleotides	O
was	O
achieved	O
by	O
heating	O
equimolar	O
concentrations	O
in	O
NaCl	O
-	O
Tris	O
-	O
EDTA	O
buffer	O
at	O
94	O
°	O
C	O
for	O
2	O
min	O
,	O
after	O
which	O
the	O
reaction	O
mixtures	O
were	O
allowed	O
to	O
slowly	O
cool	O
to	O
room	O
temperature	O
.	O

Fluorescence	O
polarisation	O
measurements	O
in	O
the	O
presence	O
and	O
absence	O
of	O
QS	O
inhibitors	O
were	O
conducted	O
as	O
described	O
previously	O
[	O
12	O
].	O

Samples	O
were	O
excited	O
at	O
480	O
nm	O
and	O
emission	O
was	O
measured	O
at	O
535	O
nm	O
on	O
a	O
Perkin	O
Elmer	O
EnVision	O
plate	O
reader	O
at	O
30	O
°	O
C	O
.	O
K	O
d	O
values	O
were	O
calculated	O
as	O
the	O
concentration	O
of	O
LuxR	B-GP
at	O
the	O
half	O
-	O
maximal	O
fractional	O
change	O
in	O
fluorescence	O
anisotropy	O
and	O
curves	O
were	O
fit	O
by	O
non	O
-	O
linear	O
regression	O
using	O
the	O
Graphpad	O
software	O
(	O
Graphpad	O
software	O
Inc	O
.,	O
La	O
Jolla	O
,	O
CA	O
,	O
USA	O
).	O

Effect	O
of	O
cinnamaldehyde	O
analogs	O
on	O
QS	O
-	O
regulated	O
phenotypes	O
in	O
vitro	O

The	O
effect	O
on	O
protease	B-GP
production	O
in	O
V	B-OG
.	I-OG
anguillarum	I-OG
LMG	I-OG
4411	I-OG
and	O
V	B-OG
.	I-OG
cholerae	I-OG
NCTC	I-OG
8457	I-OG
was	O
conducted	O
using	O
an	O
azocasein	O
assay	O
.	O

In	O
brief	O
,	O
strains	O
were	O
grown	O
overnight	O
in	O
LB	O
at	O
30	O
°	O
C	O
in	O
the	O
presence	O
and	O
absence	O
of	O
QS	O
inhibitors	O
and	O
the	O
OD	O
at	O
605	O
nm	O
was	O
determined	O
.	O

Five	O
-	O
hundred	O
microliter	O
of	O
cell	O
-	O
free	O
supernatant	O
was	O
combined	O
with	O
500	O
µl	O
azocasein	O
(	O
5	O
mg	O
/	O
ml	O
in	O
100	O
mM	O
Tris	O
,	O
pH	O
8	O
)	O
and	O
incubated	O
for	O
1	O
h	O
at	O
37	O
°	O
C	O
.	O

After	O
incubation	O
,	O
100	O
µl	O
10	O
%	O
trichloroacetic	O
acid	O
was	O
added	O
and	O
the	O
mixture	O
was	O
centrifuged	O
.	O

The	O
supernatant	O
was	O
then	O
transferred	O
to	O
700	O
µl	O
NaOH	O
(	O
525	O
mM	O
)	O
and	O
the	O
optical	O
density	O
at	O
420	O
nm	O
was	O
measured	O
.	O

The	O
effect	O
on	O
pigment	O
production	O
in	O
V	B-OG
.	I-OG
anguillarum	I-OG
LMG	I-OG
4411	I-OG
was	O
evaluated	O
as	O
described	O
previously	O
[	O
8	O
].	O

Each	O
compound	O
was	O
tested	O
twice	O
in	O
each	O
assay	O
and	O
each	O
assay	O
was	O
repeated	O
at	O
least	O
four	O
times	O
(	O
n	O
≥	O
8	O
).	O

Biofilms	O
were	O
grown	O
and	O
biofilm	O
biomass	O
was	O
quantified	O
by	O
crystal	O
violet	O
(	O
CV	O
)	O
staining	O
using	O
a	O
Perkin	O
Elmer	O
EnVision	O
plate	O
reader	O
,	O
as	O
described	O
previously	O
[	O
10	O
],	O
[	O
28	O
].	O

For	O
quantification	O
of	O
the	O
number	O
of	O
metabolically	O
active	O
cells	O
in	O
the	O
biofilm	O
,	O
a	O
resazurin	O
assay	O
was	O
used	O
[	O
28	O
].	O

Each	O
compound	O
was	O
tested	O
six	O
times	O
in	O
each	O
assay	O
and	O
each	O
assay	O
was	O
repeated	O
at	O
least	O
three	O
times	O
(	O
n	O
≥	O
18	O
).	O

The	O
effect	O
of	O
the	O
QS	O
inhibitors	O
on	O
starvation	O
response	O
of	O
several	O
Vibrio	B-OG
spp	I-OG
.	O
was	O
performed	O
as	O
described	O
previously	O
[	O
27	O
].	O

Each	O
assay	O
was	O
repeated	O
at	O
least	O
three	O
times	O
.	O

C	B-OG
.	I-OG
elegans	I-OG
challenge	O
test	O

Synchronized	O
adult	O
nematode	B-OG
populations	O
were	O
obtained	O
as	O
described	O
previously	O
[	O
29	O
].	O

For	O
the	O
survival	O
assay	O
,	O
synchronized	O
L4	B-OG
worms	I-OG
were	O
suspended	O
in	O
a	O
medium	O
containing	O
95	O
%	O
M9	O
buffer	O
,	O
5	O
%	O
BHI	O
and	O
10	O
µg	O
/	O
ml	O
cholesterol	O
(	O
Sigma	O
-	O
Aldrich	O
).	O

0	O
.	O
5	O
ml	O
of	O
this	O
suspension	O
was	O
transferred	O
to	O
the	O
well	O
of	O
a	O
24	O
-	O
well	O
plate	O
.	O

An	O
overnight	O
bacterial	O
culture	O
was	O
centrifuged	O
and	O
resuspended	O
in	O
the	O
assay	O
medium	O
and	O
standardized	O
to	O
108	O
CFU	O
/	O
ml	O
.	O

250	O
µl	O
aliquots	O
of	O
the	O
standardized	O
bacterial	O
population	O
were	O
added	O
to	O
each	O
well	O
,	O
while	O
250	O
µl	O
sterile	O
medium	O
was	O
added	O
to	O
the	O
positive	O
control	O
.	O

QS	O
inhibitors	O
were	O
added	O
to	O
the	O
test	O
-	O
wells	O
.	O

The	O
assay	O
plates	O
were	O
incubated	O
at	O
25	O
°	O
C	O
for	O
up	O
to	O
two	O
days	O
.	O

The	O
fraction	O
of	O
death	O
worms	B-OG
was	O
determined	O
by	O
counting	O
the	O
number	O
of	O
dead	O
worms	B-OG
and	O
total	O
number	O
of	O
worms	B-OG
in	O
each	O
well	O
using	O
a	O
dissecting	O
microscope	O
.	O

Each	O
compound	O
was	O
tested	O
three	O
times	O
in	O
each	O
assay	O
and	O
each	O
assay	O
was	O
repeated	O
at	O
least	O
three	O
times	O
(	O
n	O
≥	O
9	O
).	O

Investigation	O
of	O
pharmacokinetic	O
properties	O
and	O
cytotoxicity	O

The	O
molecular	O
properties	O
of	O
all	O
QS	O
inhibiting	O
compounds	O
were	O
predicted	O
using	O
a	O
commercial	O
software	O
package	O
(	O
Molinspiration	O
Cheminformatics	O
,	O
Slovensky	O
Grob	O
,	O
Slovak	O
Republic	O
).	O

Cytotoxicity	O
was	O
tested	O
on	O
human	B-OG
simian	B-OG
virus	I-OG
40	I-OG
-	O
immortalized	O
lung	O
fibroblasts	O
(	O
MRC	O
-	O
5	O
SV2	O
cells	O
;	O
European	O
Collection	O
of	O
Cell	O
Cultures	O
,	O
United	O
Kingdom	O
).	O

MRC	O
-	O
5	O
cells	O
were	O
cultured	O
in	O
Earl	O
'	O
s	O
MEM	O
(	O
Gibco	O
,	O
UK	O
)	O
+	O
5	O
%	O
FCSi	O
.	O

Assays	O
were	O
performed	O
in	O
96	O
-	O
well	O
microtiter	O
plates	O
,	O
each	O
well	O
containing	O
about	O
104	O
cells	O
.	O

After	O
3	O
days	O
incubation	O
at	O
37	O
°	O
C	O
with	O
5	O
%	O
CO2	O
,	O
cell	O
viability	O
was	O
assessed	O
fluorimetrically	O
after	O
addition	O
of	O
resazurin	O
(	O
excitation	O
and	O
emission	O
wavelength	O
of	O
550	O
nm	O
and	O
590	O
nm	O
,	O
respectively	O
).	O

The	O
results	O
are	O
expressed	O
as	O
%	O
reduction	O
in	O
cell	O
growth	O
/	O
viability	O
compared	O
to	O
untreated	O
control	O
wells	O
and	O
an	O
IC50	O
is	O
determined	O
.	O

Statistics	O

The	O
normal	O
distribution	O
of	O
the	O
data	O
was	O
checked	O
using	O
the	O
Shapiro	O
–	O
Wilk	O
test	O
.	O

Normally	O
and	O
non	O
-	O
normally	O
distributed	O
data	O
were	O
analyzed	O
using	O
an	O
independent	O
sample	O
t	O
-	O
test	O
and	O
the	O
Mann	O
–	O
Whitney	O
U	O
test	O
,	O
respectively	O
.	O

Statistical	O
analyses	O
were	O
carried	O
out	O
using	O
SPSS	O
software	O
,	O
version	O
17	O
.	O
0	O
(	O
SPSS	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
).	O

Supporting	O
Information	O

The	O
molecular	O
properties	O
of	O
the	O
different	O
compounds	O
.	O

(	O
DOC	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

